Secondhand Smoke Associated with Behavior Issues in Kids: THURSDAY

Secondhand Smoke Associated with Behavior Issues in Kids: – THURSDAY, Oct . 1, 2015 – – Early exposure to secondhand smoke can lead to behavioral complications in children, a new study suggests. Researchers analyzed data from a lot more than 5,200 primary school learners in France and found that those subjected to secondhand smoke while in the womb and/or at a age were in higher risk for behavioral problems, emotional and conduct disorders particularly. The association was strongest among children subjected to secondhand smoke both during pregnancy and after birth. However, because this was an observational study, the authors can’t say for sure that secondhand smoke caused the behavioral complications. The analysis was published online in the journal PLoS One recently. Our data indicate that passive smoking, in addition to the well-known effects on health, should also be avoided because of the behavioral disorders it might cause in children, research leader Isabella Annesi-Maesano, research director at the French Institute of Medical and Wellness Research in Paris, said within an institute news release. The results support animal research findings that nicotine in secondhand smoke may have a neurotoxic effect on the brain. Those studies found that during pregnancy, exposure to nicotine smoke cigarettes causes structural adjustments in the fetal brain, and that contact with tobacco smoke through the first a few months of life causes a protein imbalance that affects the development of neurons, the study authors said.

‘Placebo Effect’ WILL HELP Predict Response to Despair Treatment: – WEDNESDAY, Sept. 30, 2015 – – People who have depression who present improvement when taking false drugs get the greatest reap the benefits of real medications, a fresh study finds. It would appear that patients who can use their brain’s own chemical forces to combat depression get more benefit when taking antidepressants than those that lack that ability, the University of Michigan Medical College researchers found. We need to find out how to enhance the natural resiliency that some people may actually have, said research team leader Dr. Jon-Kar Zubieta, a previous Michigan faculty member who’s today at the University of Utah. The findings may help explain why responses to medicines vary among depression patients and help lead to new treatments, he and his colleagues said. For the scholarly study, 35 people with untreated main depression were told they were receiving a new depression drug before receiving existing depression drugs. But the first drug was a placebo actually, or fake medication. Patients who all had the most improvement when taking the placebo showed the strongest response in human brain regions involved in emotion and major depression. These patients were also much more likely to possess fewer depression symptoms when they took the true drug. The study was published online Sept. 30 in the journal JAMA Psychiatry. The results provide objective evidence that the brain’s own opioid system responds to both antidepressants and placebos, and that variation in this response is connected with variation in symptom alleviation, said first author Dr. Marta Pecina, a study associate professor in Michigan’s division of psychiatry. This finding gives us a biomarker for treatment response in depression – – a target way to measure neurochemical compounds involved in response, she stated in a university news release. We are able to envision that by enhancing placebo effects, we may have the ability to develop faster-acting or better antidepressants. Zubieta said the analysis results suggest that some social folks are more responsive to the intention to treat their depression. They may do better if psychotherapies or cognitive therapies that enhance the clinician-patient relationship are incorporated into their care and also antidepressant medications, he stated in the news release. The placebo effect noted in the analysis came not merely from patients’ belief that they were receiving a real drug, Zubieta said, but also from simply being in cure environment.